Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?
J Oncol Pharm Pract
.
2019 Dec;25(8):2062-2063.
doi: 10.1177/1078155219858176.
Epub 2019 Jun 21.
Authors
Yüksel Ürün
1
,
H Arzu Yaşar
1
,
Hande Turna
2
,
Saadettin Kılıçkap
3
,
Ahmet Sezer
4
,
Berna Öksüzoğlu
5
,
Nuriye Özdemir
6
,
Ma Nahit Şendur
7
,
Hüseyin Abalı
8
Affiliations
1
Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
2
Cerrahpasa Medical Faculty, Medical Oncology, Istanbul Univesity, İstanbul, Turkey.
3
Faculty of Medicine, Medical Oncology, Hacettepe University, Ankara, Turkey.
4
Adana Hospital, Medical Oncology, Baskent University, Adana, Turkey.
5
Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Medical Oncology, Ankara, Turkey.
6
Faculty of Medicine, Medical Oncology, Gazi University, Ankara, Turkey.
7
Faculty of Medicine, Medical Oncology, Yıldırım Beyazıt University, Ankara, Turkey.
8
Medical Oncology, Adana Acıbadem Hospital, Adana, Turkey.
PMID:
31226917
DOI:
10.1177/1078155219858176
No abstract available
Publication types
Letter
Comment
MeSH terms
Combined Modality Therapy
Humans
Immunotherapy*
Ipilimumab
Melanoma*
Prognosis
Substances
Ipilimumab